论文部分内容阅读
目的探讨血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)、细胞角蛋白21-1片段(CYFRA21-1)在非小细胞肺癌预后判断中的价值。方法选择2010年3月至2013年3月收治的178例非小细胞肺癌患者,按照疾病进展时间(TTP)分为5组。结果各组间NSE、CYFRA21-1和CEA含量差异无统计学意义(P>0.05)。各组间的CA125含量差异有统计学意义(P<0.05)。CEA、CYFRA21-1和CA125水平与患者的1年生存率有关。结论血清肿瘤标志物CEA、CA125、NSE和CYFRA21-1在非小细胞肺癌的预后判断中具有一定的应用价值。
Objective To investigate the clinical value of serum tumor markers CEA, CA125, NSE and CYFRA21-1 in non-small cell lung cancer Judgment value. Methods 178 patients with non-small cell lung cancer admitted from March 2010 to March 2013 were divided into 5 groups according to the time to disease (TTP). Results There was no significant difference in the contents of NSE, CYFRA21-1 and CEA between groups (P> 0.05). There was significant difference in CA125 content between groups (P <0.05). CEA, CYFRA21-1 and CA125 levels and the patient’s 1-year survival rate. Conclusion Serum tumor markers CEA, CA125, NSE and CYFRA21-1 have certain value in the prognosis of non-small cell lung cancer.